GlassScriptPhysician profile
Brian M Martinez
NPI 1083135776
$7,552.93
in general payments reported to CMS, 2019-2025
29 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,274 · 2022: $1,449 · 2023: $1,221 · 2024: $2,150 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,830.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,118.62 | 2021-2025 | |
| Edwards Lifesciences Corporation | $811.67 | 2022-2025 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $666.84 | 2021-2025 | Lifevest |
| Amgen INC. | $618.84 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $533.49 | 2023-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Bodyguardian |
| Biosense Webster, INC. | $422.60 | 2022-2024 | Nuvision Ice Catheter |
| Pfizer INC. | $355.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $348.69 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.07 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $312.01 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $285.45 | 2021-2025 | Farxiga, Wainua |
| Kiniksa Pharmaceuticals International, Plc | $269.29 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $226.77 | 2021-2024 | Xarelto |
| Abbott Laboratories | $211.77 | 2022-2024 | Gallant, Aveir |
| Impulse Dynamics (USA) INC. | $165.07 | 2024 | Optimizer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $130.74 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $121.06 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $103.11 | 2021-2023 | Arcalyst |
| Medtronic, INC. | $95.83 | 2022-2023 | Reveal Linq, Linq II |
| Alnylam Pharmaceuticals INC. | $72.49 | 2024-2025 | Onpattro, Amvuttra |
| Irhythm Technologies, INC. | $70.72 | 2021 | |
| Abiomed | $56.93 | 2025 | |
| Heartflow, INC. | $53.91 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $46.51 | 2021-2022 | |
| Atricure, INC. | $42.88 | 2024 | |
| Esperion Therapeutics, INC. | $40.31 | 2021 | |
| Amarin Pharma, INC. | $23.29 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.74 | 2021 | |
| Cvrx, INC. | $15.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.